necrostatin-1

Necrostatin-1 is a **small molecule inhibitor** that acts as an ATP-competitive, allosteric inhibitor of receptor-interacting protein kinase 1 (**RIPK1**). It selectively blocks the necroptosis pathway, a programmed, non-apoptotic form of cell death distinct from apoptosis, by targeting RIPK1 kinase activity. Necrostatin-1 thereby prevents phosphorylation and assembly of the RIPK1-RIP3-MLKL complex, which is central to the execution of necroptosis[1][7][9]. This agent has been widely used as a research tool to investigate necroptosis in varied disease models such as neurological diseases, ischemic injury, inflammation, cardiovascular conditions, and drug-induced toxicities[7][3][6]. Necrostatin-1 has demonstrated effects in reducing ischemic brain injury, decreasing inflammation, and protecting against cell death in multiple preclinical models, but suffers from poor metabolic stability and some off-target effects. More stable and specific analogues (e.g., necrostatin-1s) have been developed for improved performance in research settings[7][2].

Other names

Nec-1Nec1Nec 15-(1H-Indol-3-ylmethyl)-3-methyl-2-thioxo-4-imidazolidinoneMethylthiohydantoin-DL-tryptophanCAS 4311-88-0CAS4311-88-0CAS-4311-88-0